ERBB2 and breast carcinoma: MICAB1 PBD1G-ADCs had a curative effect in a PDX model of HER-2+ breast cancer, at doses as low as 0.05 mg/kg once weekly for eight weeks, with a complete remission rate of 100% on day 85 (Figure 4d).